CN1448167A - Medicine for treatment of pelvic inflammation, its preparation and preparing method - Google Patents
Medicine for treatment of pelvic inflammation, its preparation and preparing method Download PDFInfo
- Publication number
- CN1448167A CN1448167A CN 02116431 CN02116431A CN1448167A CN 1448167 A CN1448167 A CN 1448167A CN 02116431 CN02116431 CN 02116431 CN 02116431 A CN02116431 A CN 02116431A CN 1448167 A CN1448167 A CN 1448167A
- Authority
- CN
- China
- Prior art keywords
- medicine
- rhizoma
- parts
- herba
- granule
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000003814 drug Substances 0.000 title claims abstract description 96
- 208000029082 Pelvic Inflammatory Disease Diseases 0.000 title claims abstract description 66
- 238000002360 preparation method Methods 0.000 title claims abstract description 20
- 229940079593 drug Drugs 0.000 title claims description 42
- 238000000034 method Methods 0.000 title abstract description 9
- 239000008187 granular material Substances 0.000 claims description 85
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 42
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 36
- 238000002156 mixing Methods 0.000 claims description 19
- WHGYBXFWUBPSRW-FOUAGVGXSA-N beta-cyclodextrin Chemical compound OC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)CO)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1CO WHGYBXFWUBPSRW-FOUAGVGXSA-N 0.000 claims description 18
- 239000007788 liquid Substances 0.000 claims description 17
- 239000000341 volatile oil Substances 0.000 claims description 17
- 238000001035 drying Methods 0.000 claims description 16
- 239000007864 aqueous solution Substances 0.000 claims description 14
- 229960004756 ethanol Drugs 0.000 claims description 14
- 238000001914 filtration Methods 0.000 claims description 14
- 238000003756 stirring Methods 0.000 claims description 13
- 229960000935 dehydrated alcohol Drugs 0.000 claims description 11
- 238000010790 dilution Methods 0.000 claims description 11
- 239000012895 dilution Substances 0.000 claims description 11
- 239000003921 oil Substances 0.000 claims description 10
- 239000000243 solution Substances 0.000 claims description 10
- 239000000796 flavoring agent Substances 0.000 claims description 9
- 235000019634 flavors Nutrition 0.000 claims description 9
- 239000002994 raw material Substances 0.000 claims description 9
- 239000006228 supernatant Substances 0.000 claims description 8
- 238000004821 distillation Methods 0.000 claims description 7
- 239000002552 dosage form Substances 0.000 claims description 7
- 239000000706 filtrate Substances 0.000 claims description 7
- 239000000203 mixture Substances 0.000 claims description 7
- VYQNWZOUAUKGHI-UHFFFAOYSA-N monobenzone Chemical compound C1=CC(O)=CC=C1OCC1=CC=CC=C1 VYQNWZOUAUKGHI-UHFFFAOYSA-N 0.000 claims description 7
- 239000000843 powder Substances 0.000 claims description 7
- 238000001256 steam distillation Methods 0.000 claims description 7
- 239000004375 Dextrin Substances 0.000 claims description 6
- 229920001353 Dextrin Polymers 0.000 claims description 6
- UEDUENGHJMELGK-HYDKPPNVSA-N Stevioside Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1O[C@]12C(=C)C[C@@]3(C1)CC[C@@H]1[C@@](C)(CCC[C@]1([C@@H]3CC2)C)C(=O)O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O UEDUENGHJMELGK-HYDKPPNVSA-N 0.000 claims description 6
- 239000006071 cream Substances 0.000 claims description 6
- 235000019425 dextrin Nutrition 0.000 claims description 6
- 230000002829 reductive effect Effects 0.000 claims description 6
- 229940013618 stevioside Drugs 0.000 claims description 6
- OHHNJQXIOPOJSC-UHFFFAOYSA-N stevioside Natural products CC1(CCCC2(C)C3(C)CCC4(CC3(CCC12C)CC4=C)OC5OC(CO)C(O)C(O)C5OC6OC(CO)C(O)C(O)C6O)C(=O)OC7OC(CO)C(O)C(O)C7O OHHNJQXIOPOJSC-UHFFFAOYSA-N 0.000 claims description 6
- 235000019202 steviosides Nutrition 0.000 claims description 6
- 238000009472 formulation Methods 0.000 claims description 5
- -1 mixing Substances 0.000 claims description 5
- 230000006837 decompression Effects 0.000 claims description 4
- 238000010438 heat treatment Methods 0.000 claims description 4
- 238000012856 packing Methods 0.000 claims description 4
- 238000004064 recycling Methods 0.000 claims description 4
- 239000007787 solid Substances 0.000 claims description 4
- 238000003860 storage Methods 0.000 claims description 4
- 239000002775 capsule Substances 0.000 claims description 3
- 238000004321 preservation Methods 0.000 claims description 3
- 238000001291 vacuum drying Methods 0.000 claims description 3
- 241000405217 Viola <butterfly> Species 0.000 claims description 2
- 230000003203 everyday effect Effects 0.000 claims description 2
- 239000003826 tablet Substances 0.000 claims description 2
- 238000001816 cooling Methods 0.000 claims 1
- 238000010298 pulverizing process Methods 0.000 claims 1
- 230000000694 effects Effects 0.000 abstract description 9
- 239000000463 material Substances 0.000 abstract description 7
- 230000008569 process Effects 0.000 abstract description 2
- 231100000331 toxic Toxicity 0.000 abstract description 2
- 230000002588 toxic effect Effects 0.000 abstract description 2
- 241000736199 Paeonia Species 0.000 abstract 1
- 235000006484 Paeonia officinalis Nutrition 0.000 abstract 1
- 231100000956 nontoxicity Toxicity 0.000 abstract 1
- 239000009910 sargent gloryvine Substances 0.000 abstract 1
- 241000699670 Mus sp. Species 0.000 description 36
- 239000008280 blood Substances 0.000 description 29
- 210000004369 blood Anatomy 0.000 description 29
- 241001465754 Metazoa Species 0.000 description 22
- 230000037396 body weight Effects 0.000 description 20
- 241001038618 Ainsliaea fragrans Species 0.000 description 18
- 241000699666 Mus <mouse, genus> Species 0.000 description 18
- 238000002474 experimental method Methods 0.000 description 15
- 208000002193 Pain Diseases 0.000 description 14
- 239000000047 product Substances 0.000 description 12
- 241000588747 Klebsiella pneumoniae Species 0.000 description 11
- 241000191967 Staphylococcus aureus Species 0.000 description 11
- 230000034994 death Effects 0.000 description 11
- 201000008225 Klebsiella pneumonia Diseases 0.000 description 10
- 238000012449 Kunming mouse Methods 0.000 description 10
- 206010035717 Pneumonia klebsiella Diseases 0.000 description 10
- 239000004615 ingredient Substances 0.000 description 10
- 238000002347 injection Methods 0.000 description 10
- 239000007924 injection Substances 0.000 description 10
- 230000036407 pain Effects 0.000 description 10
- 230000004083 survival effect Effects 0.000 description 10
- 206010018691 Granuloma Diseases 0.000 description 9
- 230000001684 chronic effect Effects 0.000 description 9
- 229920000742 Cotton Polymers 0.000 description 8
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 8
- 238000002513 implantation Methods 0.000 description 8
- 239000002245 particle Substances 0.000 description 8
- 239000008188 pellet Substances 0.000 description 8
- 210000002784 stomach Anatomy 0.000 description 8
- CTQNGGLPUBDAKN-UHFFFAOYSA-N O-Xylene Chemical compound CC1=CC=CC=C1C CTQNGGLPUBDAKN-UHFFFAOYSA-N 0.000 description 7
- 201000010099 disease Diseases 0.000 description 7
- 230000001737 promoting effect Effects 0.000 description 7
- 231100000614 poison Toxicity 0.000 description 6
- 230000001681 protective effect Effects 0.000 description 6
- 241000894006 Bacteria Species 0.000 description 5
- 230000000844 anti-bacterial effect Effects 0.000 description 5
- 238000000605 extraction Methods 0.000 description 5
- 230000002401 inhibitory effect Effects 0.000 description 5
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 4
- 230000017531 blood circulation Effects 0.000 description 4
- 230000004856 capillary permeability Effects 0.000 description 4
- 239000012531 culture fluid Substances 0.000 description 4
- 239000012153 distilled water Substances 0.000 description 4
- 238000005516 engineering process Methods 0.000 description 4
- 210000004185 liver Anatomy 0.000 description 4
- 239000000825 pharmaceutical preparation Substances 0.000 description 4
- 230000008961 swelling Effects 0.000 description 4
- 238000002560 therapeutic procedure Methods 0.000 description 4
- XTWYTFMLZFPYCI-KQYNXXCUSA-N 5'-adenylphosphoric acid Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP(O)(=O)OP(O)(O)=O)[C@@H](O)[C@H]1O XTWYTFMLZFPYCI-KQYNXXCUSA-N 0.000 description 3
- XTWYTFMLZFPYCI-UHFFFAOYSA-N Adenosine diphosphate Natural products C1=NC=2C(N)=NC=NC=2N1C1OC(COP(O)(=O)OP(O)(O)=O)C(O)C1O XTWYTFMLZFPYCI-UHFFFAOYSA-N 0.000 description 3
- CEAZRRDELHUEMR-URQXQFDESA-N Gentamicin Chemical compound O1[C@H](C(C)NC)CC[C@@H](N)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](NC)[C@@](C)(O)CO2)O)[C@H](N)C[C@@H]1N CEAZRRDELHUEMR-URQXQFDESA-N 0.000 description 3
- 229930182566 Gentamicin Natural products 0.000 description 3
- 206010061218 Inflammation Diseases 0.000 description 3
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 3
- 210000000683 abdominal cavity Anatomy 0.000 description 3
- 230000009471 action Effects 0.000 description 3
- 230000001580 bacterial effect Effects 0.000 description 3
- 239000003153 chemical reaction reagent Substances 0.000 description 3
- 230000004087 circulation Effects 0.000 description 3
- 241000411851 herbal medicine Species 0.000 description 3
- 208000015181 infectious disease Diseases 0.000 description 3
- 230000007774 longterm Effects 0.000 description 3
- 239000002574 poison Substances 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 210000000952 spleen Anatomy 0.000 description 3
- 230000001629 suppression Effects 0.000 description 3
- 239000003440 toxic substance Substances 0.000 description 3
- 241000132064 Ainsliaea Species 0.000 description 2
- 241000222122 Candida albicans Species 0.000 description 2
- 241000588724 Escherichia coli Species 0.000 description 2
- 240000001624 Espostoa lanata Species 0.000 description 2
- 235000009161 Espostoa lanata Nutrition 0.000 description 2
- 206010030113 Oedema Diseases 0.000 description 2
- 241000283973 Oryctolagus cuniculus Species 0.000 description 2
- 241000589517 Pseudomonas aeruginosa Species 0.000 description 2
- 241000700159 Rattus Species 0.000 description 2
- 241000194017 Streptococcus Species 0.000 description 2
- 238000009825 accumulation Methods 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 235000019658 bitter taste Nutrition 0.000 description 2
- 229940095731 candida albicans Drugs 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 208000030373 chronic endometritis Diseases 0.000 description 2
- 238000004140 cleaning Methods 0.000 description 2
- 235000009508 confectionery Nutrition 0.000 description 2
- 230000013872 defecation Effects 0.000 description 2
- 230000006735 deficit Effects 0.000 description 2
- 230000037213 diet Effects 0.000 description 2
- 235000005911 diet Nutrition 0.000 description 2
- 230000000857 drug effect Effects 0.000 description 2
- 239000007920 enema Substances 0.000 description 2
- 230000002496 gastric effect Effects 0.000 description 2
- 238000005469 granulation Methods 0.000 description 2
- 230000003179 granulation Effects 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 238000001802 infusion Methods 0.000 description 2
- 230000005906 menstruation Effects 0.000 description 2
- 230000003340 mental effect Effects 0.000 description 2
- 230000003287 optical effect Effects 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 210000002460 smooth muscle Anatomy 0.000 description 2
- 230000001954 sterilising effect Effects 0.000 description 2
- 238000004659 sterilization and disinfection Methods 0.000 description 2
- 210000003462 vein Anatomy 0.000 description 2
- 206010000077 Abdominal mass Diseases 0.000 description 1
- 206010000087 Abdominal pain upper Diseases 0.000 description 1
- 206010061623 Adverse drug reaction Diseases 0.000 description 1
- 208000031648 Body Weight Changes Diseases 0.000 description 1
- 241000208365 Celastraceae Species 0.000 description 1
- 241000590988 Danainae Species 0.000 description 1
- 206010012335 Dependence Diseases 0.000 description 1
- QXNVGIXVLWOKEQ-UHFFFAOYSA-N Disodium Chemical compound [Na][Na] QXNVGIXVLWOKEQ-UHFFFAOYSA-N 0.000 description 1
- 206010059866 Drug resistance Diseases 0.000 description 1
- 208000030453 Drug-Related Side Effects and Adverse reaction Diseases 0.000 description 1
- 206010013789 Dry throat Diseases 0.000 description 1
- 241000792859 Enema Species 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 108060003951 Immunoglobulin Proteins 0.000 description 1
- 208000019255 Menstrual disease Diseases 0.000 description 1
- 208000000450 Pelvic Pain Diseases 0.000 description 1
- 208000004880 Polyuria Diseases 0.000 description 1
- 208000001431 Psychomotor Agitation Diseases 0.000 description 1
- 241000700157 Rattus norvegicus Species 0.000 description 1
- 206010038743 Restlessness Diseases 0.000 description 1
- 235000000336 Solanum dulcamara Nutrition 0.000 description 1
- 208000005392 Spasm Diseases 0.000 description 1
- 210000001015 abdomen Anatomy 0.000 description 1
- 230000003187 abdominal effect Effects 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 230000036592 analgesia Effects 0.000 description 1
- 230000000202 analgesic effect Effects 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 230000004579 body weight change Effects 0.000 description 1
- 230000003139 buffering effect Effects 0.000 description 1
- 235000010418 carrageenan Nutrition 0.000 description 1
- 229920001525 carrageenan Polymers 0.000 description 1
- 208000037976 chronic inflammation Diseases 0.000 description 1
- 208000037893 chronic inflammatory disorder Diseases 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 210000002808 connective tissue Anatomy 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 230000008602 contraction Effects 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 230000007850 degeneration Effects 0.000 description 1
- 230000000994 depressogenic effect Effects 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- RGLYKWWBQGJZGM-ISLYRVAYSA-N diethylstilbestrol Chemical compound C=1C=C(O)C=CC=1C(/CC)=C(\CC)C1=CC=C(O)C=C1 RGLYKWWBQGJZGM-ISLYRVAYSA-N 0.000 description 1
- 229960000452 diethylstilbestrol Drugs 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 230000035619 diuresis Effects 0.000 description 1
- 239000003651 drinking water Substances 0.000 description 1
- 235000020188 drinking water Nutrition 0.000 description 1
- 238000002651 drug therapy Methods 0.000 description 1
- 201000006549 dyspepsia Diseases 0.000 description 1
- 210000000624 ear auricle Anatomy 0.000 description 1
- 201000003511 ectopic pregnancy Diseases 0.000 description 1
- 229940095399 enema Drugs 0.000 description 1
- 210000002919 epithelial cell Anatomy 0.000 description 1
- 210000002950 fibroblast Anatomy 0.000 description 1
- 238000011049 filling Methods 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 238000003304 gavage Methods 0.000 description 1
- 229960002518 gentamicin Drugs 0.000 description 1
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 1
- 239000010931 gold Substances 0.000 description 1
- 229910052737 gold Inorganic materials 0.000 description 1
- 210000004013 groin Anatomy 0.000 description 1
- 210000003128 head Anatomy 0.000 description 1
- 208000021760 high fever Diseases 0.000 description 1
- 230000037189 immune system physiology Effects 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 102000018358 immunoglobulin Human genes 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 208000000509 infertility Diseases 0.000 description 1
- 230000036512 infertility Effects 0.000 description 1
- 231100000535 infertility Toxicity 0.000 description 1
- 208000021267 infertility disease Diseases 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 239000006210 lotion Substances 0.000 description 1
- 206010025482 malaise Diseases 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 230000002632 myometrial effect Effects 0.000 description 1
- 230000017074 necrotic cell death Effects 0.000 description 1
- 231100000957 no side effect Toxicity 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 230000000242 pagocytic effect Effects 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 230000003285 pharmacodynamic effect Effects 0.000 description 1
- OXNIZHLAWKMVMX-UHFFFAOYSA-N picric acid Chemical compound OC1=C([N+]([O-])=O)C=C([N+]([O-])=O)C=C1[N+]([O-])=O OXNIZHLAWKMVMX-UHFFFAOYSA-N 0.000 description 1
- 238000007747 plating Methods 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 238000003825 pressing Methods 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 238000011552 rat model Methods 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000000630 rising effect Effects 0.000 description 1
- 210000004999 sex organ Anatomy 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
- 230000035900 sweating Effects 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 206010042772 syncope Diseases 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 230000009897 systematic effect Effects 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 231100000820 toxicity test Toxicity 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 210000004291 uterus Anatomy 0.000 description 1
- 235000021419 vinegar Nutrition 0.000 description 1
- 239000000052 vinegar Substances 0.000 description 1
- 238000003809 water extraction Methods 0.000 description 1
Landscapes
- Medicines Containing Plant Substances (AREA)
Abstract
Description
Group | Dosage (g/kg) | Animal (N) | Survival rate (%) | Mean survival time (d) |
The blank group | ????10 | ????10 | ????1.6±1.90 | |
The pelvic inflammatory disease granule | ????14.6 | ????10 | ????10 | ????2.0±1.89 |
The pelvic inflammatory disease granule | ????29.3 | ????10 | ????30 | ????3.2±2.70 |
The pelvic inflammatory disease granule | ????58.5 | ????10 | ????20 | ????2.6±2.41 |
The Ainsliaea fragrans Champ. granule | ????21.0 | ????10 | ????10 | ????2.0±1.89 |
Claims (9)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CNB021164312A CN1186052C (en) | 2002-04-04 | 2002-04-04 | Medicine for treatment of pelvic inflammation, its preparation and preparing method |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CNB021164312A CN1186052C (en) | 2002-04-04 | 2002-04-04 | Medicine for treatment of pelvic inflammation, its preparation and preparing method |
Publications (2)
Publication Number | Publication Date |
---|---|
CN1448167A true CN1448167A (en) | 2003-10-15 |
CN1186052C CN1186052C (en) | 2005-01-26 |
Family
ID=28680717
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CNB021164312A Expired - Lifetime CN1186052C (en) | 2002-04-04 | 2002-04-04 | Medicine for treatment of pelvic inflammation, its preparation and preparing method |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN1186052C (en) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101066410B (en) * | 2007-06-01 | 2011-09-28 | 刘桂兰 | Chinese medicine preparation for treating women's chronic pelvic inflammation and its preparation process |
CN104474473A (en) * | 2014-12-04 | 2015-04-01 | 吴瑞岚 | Traditional Chinese medicine composition for treating gynecologic inflammation and preparation method thereof |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN107050178A (en) * | 2017-02-28 | 2017-08-18 | 河南中医药大学 | A kind of Chinese medicine for treating cervical carcinoma |
-
2002
- 2002-04-04 CN CNB021164312A patent/CN1186052C/en not_active Expired - Lifetime
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101066410B (en) * | 2007-06-01 | 2011-09-28 | 刘桂兰 | Chinese medicine preparation for treating women's chronic pelvic inflammation and its preparation process |
CN104474473A (en) * | 2014-12-04 | 2015-04-01 | 吴瑞岚 | Traditional Chinese medicine composition for treating gynecologic inflammation and preparation method thereof |
CN104474473B (en) * | 2014-12-04 | 2017-11-10 | 吴瑞岚 | A kind of Chinese medicine composition for treating gynaecological imflammation and preparation method thereof |
Also Published As
Publication number | Publication date |
---|---|
CN1186052C (en) | 2005-01-26 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN1857618A (en) | Chinese medicine preparation for reducing sugar | |
CN101947284B (en) | Traditional Chinese medicinal composition for treating diabetes and preparation method thereof | |
CN102813801B (en) | Traditional Tibetan medicine for treating cough and preparation method thereof | |
CN103520572B (en) | A kind of Chinese medicine composition being used for the treatment of atopic dermatitis and preparation method thereof | |
CN102178804B (en) | Chinese medicinal composition for treating perianal eczema and preparation method thereof | |
CN103948786A (en) | Traditional Chinese medicine for treating diabetes | |
CN104940479A (en) | TCM composition for treating AD diseases | |
CN1327875C (en) | Chinese medicine formulation for treating chronic pelvic inflammation and its preparing method | |
CN106361830B (en) | Rhubarb powder and preparation method thereof | |
CN1951485A (en) | An antivirus medicament | |
CN102652819B (en) | Fuyankang dispersible tablet and preparation method thereof | |
CN1186052C (en) | Medicine for treatment of pelvic inflammation, its preparation and preparing method | |
CN1327874C (en) | Chinese medicine formulation for treating chronic prostatitis and its preparing method | |
CN103157048B (en) | Traditional Chinese medicine composition for treating chronic pelvic inflammation and preparation method thereof | |
CN1298351C (en) | Chinese medicine oral preparaton for treating urinary system infestation and its preparation method | |
CN1772239A (en) | Chinese medicine prepn for treating vaginitis and cervicitis | |
CN103705857B (en) | For preventing the Chinese medicine composition of oral cavity radiomucitis | |
CN103028028B (en) | Traditional Chinese medicine agent for treating primary hepatic carcinoma | |
CN102335362A (en) | Traditional Chinese medicine for treating insulin resistance of type 2 diabetes | |
CN101167915B (en) | Traditional Chinese medicine for treating chronic superficial gastritis and its preparation method | |
CN100577195C (en) | Application of Chinese medicine composiiton in preparing medicine for treating salpingitis, oophoritic cyst, colpitis and cervicitis | |
CN1299755C (en) | Cinnamon compound medicine, and its preparing method and use | |
CN105920436A (en) | Medicinal preparation for treating lung cancer and preparation method thereof | |
CN104940478A (en) | Ginseng antler brain-nourishing prescription for treating AD diseases | |
CN104189646A (en) | Traditional Chinese medicine for treating damp-heat type 2 diabetes mellitus and preparation method thereof |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
C56 | Change in the name or address of the patentee |
Owner name: LUNAN PHARMACEUTICAL GROUP CO., LTD. Free format text: FORMER NAME OR ADDRESS: LUNAN PHARMACY CO. LTD. |
|
CP03 | Change of name, title or address |
Address after: 276005 No. 209 Hongqi Road, Shandong, Linyi Patentee after: Lunan Pharmaceutical Group Co., Ltd. Address before: 276003 No. 107, No. 1, Linxi, Shandong, Linyi Patentee before: Lunan Pharmacy Co., Ltd. |
|
EE01 | Entry into force of recordation of patent licensing contract |
Assignee: Shandong Xinshidai Pharmaceutical Industry Co., Ltd. Assignor: Lunan Pharmaceutical Group Co., Ltd. Contract record no.: 2010370000511 Denomination of invention: Medicine for treatment of pelvic inflammation, its preparation and preparing method Granted publication date: 20050126 License type: Exclusive License Open date: 20031015 Record date: 20100909 |
|
CX01 | Expiry of patent term | ||
CX01 | Expiry of patent term |
Granted publication date: 20050126 |